Iovance Biotherapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +96.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 14.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 34.3% | Better than 39% |
| Operating margin | -151.1% | Better than 6% |
| Net margin | -148.4% | Better than 6% |
| Return on equity | -55.5% | Better than 8% |
| Return on invested capital | -52.9% | Better than 6% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -16.8% | Better than 36% |
| 6-month return | 67.9% | Better than 97% |
| 12-month return (ex latest month) | 531.3% | Better than 100% |
| Distance below 52-week high | 55.1% | Better than 14% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.2x | Better than 75% |
| Debt to assets | 5.4% | Better than 79% |
| Interest coverage | -56.1x | Better than 7% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 137.4% | Better than 89% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 7.31
- Open
- 7.17
- Day range
- 6.77 - 7.40
- Avg price
- 6.99
- Volume
- 13.73M
- Turnover
- 95.95M
- Turnover ratei
- 3.40%
- Volume ratioi
- 1.51
- Amplitudei
- 8.55%
- 52-week rangei
- 2.08 - 15.37
Valuation
- P/Ei
- -6.33
- P/E (TTM)i
- -14.08
- P/Bi
- 3.93
- EPSi
- -1.09
- Book value / shi
- 1.76
- Net profit
- -504.29M
- Net assets
- 812.89M
Share structure
- Market cap
- 3.19B
- Float capi
- 2.79B
- Shares out
- 462.66M
- Float sharesi
- 403.97M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
55.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-50.98M net over the window
Short interest
- Shares short
- 65.19M
- % of floati
- 14.39%
- Days to coveri
- 4.17
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Iovance Biotherapeutics (IOVA)?
Iovance Biotherapeutics last traded at 6.90. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Iovance Biotherapeutics's market cap?
About 3.19B.
What is the P/E ratio of Iovance Biotherapeutics?
The trailing twelve-month P/E is -14.08. The Valuation tab shows it against the stock's own five-year range.
Does Iovance Biotherapeutics pay a dividend?
Iovance Biotherapeutics does not currently pay a regular dividend.
Is Iovance Biotherapeutics a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 16.38, which implies 137.4% upside from the current price. This is not investment advice.
What is Iovance Biotherapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Iovance Biotherapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:59:47 · For reference only, not investment advice and not tailored to your situation.
Iovance Biotherapeutics discussion 0 comments